Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study

BACKGROUND: Type 2 Diabetes Mellitus (T2DM) patients are exposed to a 7.5 times higher risk of hypoglycemia while fasting during Ramadan. Relevant diabetes guidelines prioritize the use of SGLT2 inhibitors over other classes. There is a great need to enrich data on their safe and effective use by fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Samkari, Mayada M., Bokhari, Neda'a S., Alhajaji, Raghad, Ahmed, Malaz E., Al Raddadi, Ahmad, Bahget, Alaa K., Saleh, Sarah F., Aljehani, Faisal, Alzahrani, Saud H., Alsifyani, Sarah S., Samkari, May M., Badr, Aisha F., Alalawi, Mai, Al Sulaiman, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205764/
https://www.ncbi.nlm.nih.gov/pubmed/37234349
http://dx.doi.org/10.1016/j.jsps.2023.04.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205764/
https://www.ncbi.nlm.nih.gov/pubmed/37234349
http://dx.doi.org/10.1016/j.jsps.2023.04.022

Ejemplares similares